165 related articles for article (PubMed ID: 2619781)
1. Suitability of long-acting metoclopramide for prophylaxis of chemotherapy-induced delayed nausea and vomiting.
Wilder-Smith C; Schimke J; Vergin H; Senn HJ
Arzneimittelforschung; 1989 Nov; 39(11):1464-7. PubMed ID: 2619781
[TBL] [Abstract][Full Text] [Related]
2. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
3. [The control of chemotherapy-induced nausea and vomiting].
Shinkai T; Saijo N; Sawamura N; Funaki U; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Shimizu E
Gan No Rinsho; 1985 Jun; 31(7):779-91. PubMed ID: 3897622
[TBL] [Abstract][Full Text] [Related]
4. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
5. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
6. [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
Nino S; Umehara H; Inoue I; Tamura T; Sasaki Y; Sakurai M; Shinkai T; Eguchi K; Saijo N; Suemasu K
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2881-4. PubMed ID: 3310905
[TBL] [Abstract][Full Text] [Related]
7. [Recent advances in the management of chemotherapy-induced emesis].
Murakami M; Ota K
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):401-11. PubMed ID: 3006594
[TBL] [Abstract][Full Text] [Related]
8. Management of chemotherapy-induced nausea and vomiting.
Tortorice PV; O'Connell MB
Pharmacotherapy; 1990; 10(2):129-45. PubMed ID: 2190193
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of two outpatient antiemetic regimens for cancer chemotherapy.
Pruitt BT; Justice RL; Periman P
Tex Med; 1985 Jul; 81(7):44-5. PubMed ID: 3898458
[No Abstract] [Full Text] [Related]
11. [Nausea and vomiting during treatment with cytostatics].
Kaasa S; Mella O; Kvikstad A
Tidsskr Nor Laegeforen; 1991 Mar; 111(8):941-4. PubMed ID: 2042209
[TBL] [Abstract][Full Text] [Related]
12. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND
J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis.
van Groeningen CJ; Gall HE; Simons KA; van Loenen AC; Knobf MK; Nauta J; Vermorken JB; Pinedo HM
Neth J Med; 1989 Dec; 35(5-6):283-94. PubMed ID: 2699653
[TBL] [Abstract][Full Text] [Related]
15. Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group.
Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Andersson H; Hansen O; Sørensen BT; Räisänen I
Anticancer Drugs; 1995 Feb; 6 Suppl 1():31-6. PubMed ID: 7749168
[TBL] [Abstract][Full Text] [Related]
16. [High dose metoclopramide during cancer chemotherapy. Phase II study in 80 consecutive patients].
Bui NB; Marit G; Albin H; Durand M; Mauriac L; Hoerni B
Bull Cancer; 1982; 69(4):330-5. PubMed ID: 7150789
[TBL] [Abstract][Full Text] [Related]
17. [Metoclopramide plasma levels following oral administration of high doses for prophylaxis of emesis in cytostatic therapy].
Vergin H; Köhler M; Senn HJ
Arzneimittelforschung; 1984; 34(11):1595-7. PubMed ID: 6543137
[TBL] [Abstract][Full Text] [Related]
18. Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy.
Osoba D; Erlichman C; Willan AR; Levitt M; Pater JL
Clin Invest Med; 1986 Nov; 9(4):225-31. PubMed ID: 3542325
[TBL] [Abstract][Full Text] [Related]
19. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the management of nausea and vomiting caused by antineoplastic agents.
Merrifield KR; Chaffee BJ
Clin Pharm; 1989 Mar; 8(3):187-99. PubMed ID: 2650957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
